Izatan Tab.
Negotiable Min Order Quantity Unit
- Required Quantity
-
- Place of Origin
- Payment Terms
- Negotiable
- Production method
- Negotiable
- Shipping / Lead Time
- Negotiable / Negotiable
- Keyword
- hypertension, circulatory system, irbesartan
- Category
- Health & Medical
DONGWHA PHARM CO LTD
- Country / Year Established
- South Korea / 1897
- Business type
- Manufacturer
- Verified Certificate
-
16
Product name | Izatan Tab. | Certification | - |
---|---|---|---|
Category | Health & Medical | Ingredients | - |
Keyword | hypertension , circulatory system , irbesartan | Unit Size | - |
Brand name | - | Unit Weigh | - |
origin | Stock | - | |
Supply type | - | HS code | - |
Product Information
1. Category
: Ethical > Circulatory System
2. Ingredients
: 1 tablet contains
Irbesartan - 150mg
3. Indications
1) Treatment of essential hypertension.
2) Treatment of renal disease in patients with hypertension and type 2 diabetes mellitus as part of and antihypertensive medicinal product regimen.
4. Dosage
: The usual recommended initial and maintenance dose is 150mg once daily, with or without food. This drug at a dose of 150mg once daily generally provides a better 24 hour blood pressure control than 75mg. However, initiation of therapy with 75mg could be considered, particularly in haemodialysed patients and in the elderly over 75 years.
In patients insufficiently controlled with 150mg once daily, the dose of Izatan can be increased to 300mg, or other anti-hypertensive agents can be added. In particular, the addition of a diuretic such as hydrochlorothiazide has been shown to have an additive effect with Izatan.
In hypertensive type 2 diabetic patients therapy should be initiated at 150mg irbesartan once daily and titrated up to 300mg once daily as the preferred maintenance dose for treatment of renal disaese. The demonstration of renal benefit of Izatan in hytertensive type 2 diabetic patients is based on studies where irbesartan was used in addition to other antihypertensive agents, as needed, to reach target blood pressure.
Renal impairment: no dosage adjustment is necessary in patients with impaired renal function. A lower starting dose(75mg) should be considered for patients undergoing haemodialysis.
Elderly patients: although consideration should be given to initiation therapy with 75mg in patients over 75 years of age, dosage adjustment is not usually necessary for the elderly.
5. Pack Size
: 30T, 100T
6. Related Disease
: Cardiovascular system
B2B Trade
Price (FOB) | Negotiable | transportation | - |
---|---|---|---|
MOQ | Negotiable | Leadtime | Negotiable |
Payment Options | Negotiable | Shipping time | Negotiable |
- President
- KI HWAN PARK
- Address
- 6-8F, 24, NAMDAEMUN-RO, 9-GIL, JUNG-GU, SEOUL, 04522, KOREA, Jung-gu, Seoul, Korea
- Product Category
- Pharmaceuticals
- Year Established
- 1897
- No. of Total Employees
- 501-1000
- Company introduction
-
In 1897, a small company named ‘Dong WhaYakbang’ was established in Jeong-dong, where Western culture was introduced ata turbulent time in Korean history. A royal court officer of the ChosunDynasty, Byung Ho Min, created Korea’s first Western-style medicine byintegrating the advantages of Western medical techniques into the royal court’ssecret recipe.
This digestive medicine, known as WhalMyung Su, meaning ‘life-saving water’, soothed people’s pain in those turbulenttimes and became a reliable “comrade” for independence fighters. Since itscreation, Whal Myung Su has been loved as the nation’s favorite digestivemedicine for 117 years amid ever-changing social circumstances and greatturmoil due to the company’s conviction that ‘We will save people with goodmedicine’.
We run our company according to the beliefthat making medicine is not a simple business activity, but a sacred andbeautiful duty that brings happiness to humans.
Honorable titles bestowed by the people,such as ‘The First’ or ‘The Best’, are earned through such a conviction.
Now, Dong Wha Pharm, as Korea’s first andoldest pharmaceutical company, is ready to launch a new era of 100 years basedon such pride. We will abide by our founder’s first intent, ‘Do not make anymedicines but good medicines’. We will be reborn as a self-regulating, adaptivecompany through change and innovation. Based on our accumulated technology and experience,we will make new products of the highest quality. With our happiness managementphilosophy, we will make Dong Wha as the company where each employee can havebig dreams.
Lastly, we will contribute to human healthand happiness. Please join us in exploring this new era.
* Dong Wha Pharm Research Institute, the Backbone of New MedicineDevelopment
Since its establishment in 1973, Dong WhaPharm Research Institute has developed numerous superior medicines and the mostadvanced drugs. It is now set to become a global hub for new drug development.
In order to create a new world-class drug,the research center will focus on R&D (Research and Development), andexpand its assistance and investment on fostering professional human resources.
* World-class advanced production facilities, Chungju cGMP plant
In 2009, at the Chungju Industrial Complex,Dong Wha Pharm completed the construction of state-of-the-art production facilities,comprising of four stories aboveground and one underground level with a totalof 82,500m2 including total floor space of 52,644m2.
The Chungju Plant is equipped withequipment and facilities that satisfy Current Good Manufacturing Practice(cGMP) Regulations of US F. D. A. In addition, the plant has been evaluated asa world-class pharmaceutical company by the installment of high-tech plantautomation system.
Dong Wha Pharm pursues 100% zero defectswith its independent quality assurance system, which encompasses the procurementof raw materials, production processes, packaging and shipment.
- Main Markets
-
Germany
Indonesia
Japan
Mexico
Portugal
Spain
U.S.A
Viet Nam
- Factory Information
-
DONG WHA CHUNGJU PLANT
- Main Product